A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
NCT ID: NCT01677390
Last Updated: 2014-01-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
4 participants
INTERVENTIONAL
2012-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
NCT01114230
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
NCT01715935
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
NCT01672775
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
NCT01491672
Study of the Combination of CM082 With Everolimus in Patients With mRCC
NCT02577458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
SGN-75, everolimus
SGN-75
1-2 mg/kg IV every 21 days
everolimus
10 mg PO daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGN-75
1-2 mg/kg IV every 21 days
everolimus
10 mg PO daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Previously treated with at least 1 tyrosine kinase inhibitor (TKI)
* Measurable disease
* Eastern Cooperative Oncology Group performance status 0 or 1
* Adequate lung and renal function
Exclusion Criteria
* Received more than one prior treatment with an mTOR inhibitor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seagen Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elaina Gartner, MD
Role: STUDY_DIRECTOR
Seagen Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Cancer Center
Stanford, California, United States
Rocky Mountain Cancer Centers - Midtown
Denver, Colorado, United States
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
Chapel Hill, North Carolina, United States
Miriam Hospital, The
Providence, Rhode Island, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Seattle Cancer Care Alliance / University of Washington
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SGN75-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.